Updated:
SleepScore Labs
Founded in 2016 as a joint venture by ResMed, Dr. Oz's Sharecare, and Pegasus Capital Advisors, SleepScore Labs operates at the intersection of consumer...
SleepScore Labs
Founded in 2016 as a joint venture by ResMed, Dr. Oz's Sharecare, and Pegasus Capital Advisors, SleepScore Labs operates at the intersection of consumer wellness and clinical sleep science. The company commercialized a radar-based, non-contact sleep tracker that competes in the hardware space against wearables, but differentiates by its designated medical-grade rigor and data-driven personalization engine. ResMed, the CPAP giant, provided the initial core sensor technology, giving it a direct lineage to regulated respiratory care. Roy Raymann, a former Apple health executive and Philips sleep researcher, leads the scientific strategy to position the data as a bridge between consumer habits and clinical-grade analysis. The firm monetizes its dataset through two channels. First, a direct-to-consumer app that sells improvement programs and sleep tracking services. Second, a B2B licensing and API platform that has attracted consumer goods and pharmaceutical partners testing products from mattresses and pillows to aromatherapy and nutritional supplements. Known commercial relationships have included evaluations of IFF's sensory ingredients on sleep quality (per public record, 2022) and product efficacy studies for bedding companies like Bedgear. The company holds a global footprint with offices in Carlsbad and a historic presence in San Francisco and Philadelphia, with its user data spanning over 150 countries. SleepScore has completed multiple financing rounds totaling roughly $15 million (per PitchBook, 2023) including a $3.1 million preferred equity raise in 2023 to fund its shift toward a remote clinical trial platform. The full employee count has never been publicly filed, but the operation has historically run a lean team across data science, sleep research, and business development. In July 2024: The company released its latest SleepScore Max wearable-free tracker, integrating it with a revamped AI coaching feature for personalized sleep plans (per the firm, July 2024). The company's architecture is unusual for a health-tech venture — it is neither a pure software startup nor a medical device manufacturer. Its structural edge comes from its data moat: a non-wearable, ambient sensing method that captures sleep without user compliance friction, combined with 13 years of longitudinal data collection from an opt-in consumer base. That dataset positions it as a potential acquisition target or charter-licensing partner for large pharma and CPG firms conducting decentralized sleep-related clinical validation, blurring the line between commercial wellness and clinical research infrastructure.
General information
Firm type
Asset Manager
Year founded
2016
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Carlsbad
Corporate office
Carlsbad, CA, United States
Principals
Roy Raymann
Chief Scientific Officer
Sector focus
Frequently asked questions
Who owns SleepScore Labs?
SleepScore Labs was originally formed as a joint venture between ResMed, Sharecare, and Pegasus Capital Advisors in 2016. It has since raised independent capital through multiple funding rounds, though current equity distribution is not publicly disclosed. ResMed's foundational technology and Dr. Mehmet Oz's consumer wellness network remain central to the company's origin story.
How does SleepScore Labs make money?
Revenue comes from two primary streams: consumer-facing sales of sleep improvement programs and hardware like the SleepScore Max tracker, and a B2B licensing model where partners access the company's API and data analytics for product validation. Companies in bedding, fragrance, and nutritional supplements have paid for efficacy studies that use SleepScore's objective dataset to validate how their products improve restorative sleep.
What technology does SleepScore use to track sleep without a wearable?
SleepScore's devices use low-power, short-range sonar — essentially echolocation — to detect breathing patterns and body movement without physical contact with the user. The radar-based approach was originally developed for medical-grade sleep apnea screening. The signal processing algorithms parse raw RF reflections into sleep staging, classifying light sleep, deep sleep, and REM, then train a recommendation engine on that structured sleep architecture data.
How large is SleepScore's sleep dataset?
The firm has stated it has collected an objective dataset exceeding 20 million nights of sleep, gathered from consumers across more than 150 countries over 13 years. This dataset includes raw respiratory rate, movement, and derived sleep-stage labels, making it one of the largest longitudinal sleep databases not controlled by a wearables manufacturer or a pure academic center.
Is SleepScore Labs a medical device company?
No. While the technology lineage comes from regulated medical device development at ResMed, SleepScore Labs deliberately positions its products in the wellness and consumer health space, avoiding FDA clearance as a diagnostic tool. This regulatory posture allows faster product iteration and direct-to-consumer marketing that a cleared medical device cannot support.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: